Contraception

A recent study revealed Medicaid patients encounter significant obstacles to postpartum sterilization, shedding light on crucial health care access issues.

Online orders began this week for the first over the over-the-counter contraceptive, Opill (norgestrel; Perrigo).

A recent study delves into how serum estradiol decline preceding human chorionic gonadotropin administration affects in vitro fertilization outcomes, particularly among patients without oral contraceptive pretreatment, shedding light on the importance of monitoring during controlled ovarian hyperstimulation.

A randomized trial among young Kenya women showed the post-exposure prophylactic was insignificantly more effective in preventing chlamydia, gonorrhea and syphilis—largely due to inadherence.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Discover effective counseling techniques and overcome barriers to empower adolescents in making informed decisions about contraception, fostering trust, confidentiality, and autonomy in reproductive health care.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Uncover the latest findings on contraceptive methods as researchers delve into the safety, efficacy, and compliance rates of parenteral and oral hormonal contraceptives.

New findings have revealed a decline in emergency contraception-related emergency department visits, indicating increased demand.

A recent study revealed the aftermath of the Dobbs decision, with college students expressing anger and fear, facing pressure to switch to effective contraception.

Explore the potential of monoclonal antibodies for contraception and sexually transmitted infection prevention, providing a comprehensive review of their safety, efficacy, and pharmacokinetics.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

The Biden-Harris administration, has released comprehensive guidance through Frequently Asked Questions to eliminate barriers to contraception, ensuring access to FDA-approved contraceptives at no cost, following President Biden's 2023 Executive Order.

Agile Therapeutics has provided insights on strengthening the Affordable Care Act's contraceptive coverage, with a recent House Committee report revealing barriers, inequalities, and recommended changes.

The Supreme Court's upcoming decision on mifepristone, a key abortion medication, may alter access, introducing potential restrictions and impacting the landscape of abortion rights.

Daré Bioscience has commenced a pivotal phase 3 clinical trial for ovaprene, an intravaginal contraceptive that releases a locally acting agent to prevent sperm entry into the cervical canal, marking a significant step towards a non-hormonal contraceptive option for women.

A recent study reveals gaps in reproductive health services for women with disabilities, highlighting a 69% likelihood of encountering barriers, including logistical and access challenges.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

The US District Court for the District of Arizona issued an order against Arizona-based company Smart Women’s Choice, Inc, following a complaint by the US Department of Justice, alleging the distribution of unapproved new drugs in violation of the Federal Food, Drug, and Cosmetic Act.

In a recent study, patients who were treated for heavy menstrual bleeding with the levonorgestrel intrauterine system had similar changes in bleeding-related quality of life as those using combined oral contraceptives for treatment.

Women of reproductive age often use combined hormonal contraceptives, which are available orally, as a vaginal ring, or as a transdermal patch. However, CHCs are associated with increased risks of venous thromboembolism and myocardial infarction (MI).

In a recent study, venous thromboembolism risk among oral contraceptive users was accurately measured by genetic variants.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

In a recent study, negative mental health symptoms such as increased anxiety were observed among combined oral contraceptive users when treatment was paused.

In a recent study, active-duty US Army servicewomen after did not use long-active reversible contraception within 3 months after delivery.

In a recent study, transgender women had reduced sperm quality compared to cisgender men, and transgender men used contraception at similar rates to cisgender women.

The IPP LARC program “allowed for the provision of LARCs for women who had limited to no funds or access, especially in the postpartum period,” according to study authors of a poster presented at the 2023 Society of OB/GYN Hospitalists Annual Clinical Meeting in Chicago, Illinois.

Marci Bowers, MD, shares the biggest takeaways from her presentation on transgender reproductive care, presented at the 2023 Society of OB/GYN Hospitalists Annual Clinical Meeting in Chicago, Illinois.

Angela Dempsey, MD, MPH, gives her insights on how to advocate for your patients in post-Roe America, which was presented during her session at the recent 2023 Society of OB/GYN Hospitalists Annual Clinical Meeting in Chicago, Illinois.

In a recent study, effective contraceptive use was decreased among women enrolled in both Medicaid and Medicare compared to Medicaid only.